Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Oct 28, 2020-- ARIKAYCE is the First and Only Therapy Approved in Both the European Union and United States for This Difficult-To-Treat Condition --
-
Sep 30, 2020- Initiated Phase 1 study of treprostinil palmitil inhalation powder (TPIP); Phase 2a study in pulmonary arterial hypertension planned for 2021 -
-
Sep 16, 2020
-
Sep 9, 2020
-
Sep 7, 2020--New Data from WILLOW Study also Presented During Late-Breaking Session at European Respiratory Society International Congress--
-
Aug 6, 2020--ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $42.5 Million for Second Quarter 2020--
-
Jul 24, 2020- If Approved, ARIKAYCE Will Be First and Only Therapy in the European Union for This Difficult-to-Treat Condition -
-
Jul 7, 2020--First update to treatment guidelines in more than a decade, marking important milestone in patient care--
-
Jun 24, 2020--Brensocatib Shown to Reduce Time to First Pulmonary Exacerbation and Reduce Rate of Exacerbations Versus Placebo--
-
Jun 8, 2020--Full Results from Phase 2 WILLOW Study of Brensocatib in NCFBE to be Presented at Virtual ATS Session on June 24, 2020--
-
May 26, 2020
-
May 20, 2020Insmed to Showcase New Brensocatib Data at American Thoracic Society Virtual Clinical Trials Session-Results from Phase 2 WILLOW Study of Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis to be Presented-
-
Apr 30, 2020--Company Supports Investigator-Initiated Study of Brensocatib (Formerly INS1007) in Severe COVID-19 and Continues to Advance Development in Bronchiectasis--
-
Apr 23, 2020--Insmed to support STOP-COVID19 Study, Expected to Begin in the UK in May 2020--
-
Mar 16, 2020-- Company Submits New Drug Application in Japan for ARIKAYCE® (amikacin liposome inhalation suspension) for the Treatment of Patients with NTM Lung Disease Caused by MAC --
-
Mar 4, 2020-- Management of common adverse events through physician-guided measures resulted in symptomatic improvement --
-
Feb 25, 2020--ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $45.7 Million for the Fourth Quarter 2019 and $136.5 Million for the Full Year 2019--
-
Feb 3, 2020-- Study Achieves Primary Endpoint with Statistically Significant Improvement in Time to First Exacerbation for Both Dosage Strengths of INS1007 Versus Placebo --
-
Nov 26, 2019
-
Nov 14, 2019-Drayton Wise named Senior Vice President, Head of U.S.
-
Nov 5, 2019
-
Oct 30, 2019--ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $38.9 Million for the Third Quarter of 2019--
-
Sep 3, 2019
